Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

WANG Jing, ZHAO Na-ping, SHU Li-xin, LIU Bin, ZHANG Wan-lu, YAN Tian-hong, PAN Yong-hua, ZHANG Li. The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(3): 184-187,203.
Citation: WANG Jing, ZHAO Na-ping, SHU Li-xin, LIU Bin, ZHANG Wan-lu, YAN Tian-hong, PAN Yong-hua, ZHANG Li. The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(3): 184-187,203.

The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer

  • Received Date: 2010-06-22
  • Rev Recd Date: 2011-01-11
  • Objective To investigate the efficacy of Shenmai injection combined TE chemotherapy regime in the treatment of breast cancer and the influence to the quality of life in breast cancer patient. Methods 22 patients with pathologically confirmed advanced breast cancer aged from 34 to 72 were randomly divided into experimental group (TE plus Shenmai injection treatment group) and the control group (only with TE chemotherapy group). The efficacy ,side effects and blood indices were observed and analyzed. All patients received two or more cycles of treatment. SPSS10.0 statistical software was used to statistical analysis. Results 22 cases could be evaluated.The effective rate of treatment group (CR+PR) was 54.55%, and the rate of control group was 63.64%. There was no significant difference between two groups (P>0.05); clinical benefit rate was 81.82% in treatment group, and 72.73% in control group, which had no significant difference between groups (P>0.05). The main adverse events in both groups were from the blood system. compared with the control group, which had statistically significant (P<0.05) between two groups. Other adverse reactions had the similar incidence in two groups and had not statistically significant (P>0.05). Conclusion TE Shenmai injection in the treatment of breast cancer was effective and well tolerated, plus Shenmai injection could improve the quality of life in cancer patients, reduce the chemotherapy-induced hematological toxicity and non-hematologic toxicity.
  • [1] 李佩文,李 学.中医肿瘤临床手册[M].上海:上海科学技术出版社,2006:145. [2] Mass HB. Endocrine therapy for advanced breast cancer [J].Breast Cancer Res Treat,1992,21:15. [3] 赵 强,常 英,潘 靖.云硒冲剂对乳腺癌术后化疗患者免疫功能的影响[J].药学实践杂志. 2004,22(3):156. [4] 赵晓辉,郝春芳,佟仲生.紫杉醇单药每周方案治疗老年转移性乳腺癌的临床疗效观察[J].中华乳腺病杂志,2009,3(5):17. [5] 张代钊,余桂清,李佩文.癌症放化疗副反应的中医药防治研究[J].中医杂志,1994,35 (8):498. [6] 陈小红,高瑞兰,徐卫红,等.人参皂甙对红系,粒单系,巨核系细胞株的增殖及转录因子的诱导作用[J].中国中西医结合杂志,2001,21(1) :40. [7] 冯培芳,刘鲁明,沈玉英,等.参麦注射液对晚期癌症患者sIL-2R、LAK及NK细胞活性影响[J].中国中西医结合杂志,1995,15 (2):87. [8] 钱 华,林胜友,刘鲁明,等.参麦注射液对肿瘤化疗的减毒作用[J].浙江中医学院学报,1995,19 (2):32.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(2958) PDF downloads(173) Cited by()

Related
Proportional views

The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer

Abstract: Objective To investigate the efficacy of Shenmai injection combined TE chemotherapy regime in the treatment of breast cancer and the influence to the quality of life in breast cancer patient. Methods 22 patients with pathologically confirmed advanced breast cancer aged from 34 to 72 were randomly divided into experimental group (TE plus Shenmai injection treatment group) and the control group (only with TE chemotherapy group). The efficacy ,side effects and blood indices were observed and analyzed. All patients received two or more cycles of treatment. SPSS10.0 statistical software was used to statistical analysis. Results 22 cases could be evaluated.The effective rate of treatment group (CR+PR) was 54.55%, and the rate of control group was 63.64%. There was no significant difference between two groups (P>0.05); clinical benefit rate was 81.82% in treatment group, and 72.73% in control group, which had no significant difference between groups (P>0.05). The main adverse events in both groups were from the blood system. compared with the control group, which had statistically significant (P<0.05) between two groups. Other adverse reactions had the similar incidence in two groups and had not statistically significant (P>0.05). Conclusion TE Shenmai injection in the treatment of breast cancer was effective and well tolerated, plus Shenmai injection could improve the quality of life in cancer patients, reduce the chemotherapy-induced hematological toxicity and non-hematologic toxicity.

WANG Jing, ZHAO Na-ping, SHU Li-xin, LIU Bin, ZHANG Wan-lu, YAN Tian-hong, PAN Yong-hua, ZHANG Li. The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(3): 184-187,203.
Citation: WANG Jing, ZHAO Na-ping, SHU Li-xin, LIU Bin, ZHANG Wan-lu, YAN Tian-hong, PAN Yong-hua, ZHANG Li. The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(3): 184-187,203.
Reference (1)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return